Predictors that influence contralateral prophylactic mastectomy election among women with ductal carcinoma in situ who were evaluated for brca genetic testing

Annals of Surgical Oncology

Volumn 21, Issue 11, 2014, Pages 3466-3472

  Elsayegh, Nisreen ^a   Kuerer, Henry M ^a   Lin, Heather ^a   Gutierrez Barrera, Angelica M ^a   Jackson, Michelle ^a   Muse, Kimberly I ^a   Litton, Jennifer K ^a   Albarracin, Constance ^a   Afrough, Aimaz ^a   Hortobagyi, Gabriel N ^a   Arun, Banu K ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; ARTICLE; BRCA GENE; CANCER PATIENT; CANCER SURGERY; CONTRALATERAL PROPHYLACTIC MASTECTOMY; FAMILY HISTORY; FEMALE; GENE MUTATION; GENETIC COUNSELING; GENETIC SCREENING; HUMAN; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MASTECTOMY; ONCOGENE; RETROSPECTIVE STUDY; BREAST NEOPLASMS; CANCER GRADING; CANCER STAGING; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FOLLOW UP; GENETICS; MIDDLE AGED; MUTATION; OVARIAN NEOPLASMS; PATHOLOGY; PROGNOSIS;

BRCA1 PROTEIN; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN; BRCA2 PROTEIN, HUMAN;

AGE FACTORS; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; FOLLOW-UP STUDIES; GENETIC TESTING; HUMANS; MASTECTOMY; MIDDLE AGED; MUTATION; NEOPLASM GRADING; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 84922545276     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-3747-x     Document Type: Article

References (25)

1. Bayraktar S, Elsayegh N, Gutierrez Barrera A, et al. Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ. Cancer. 2012;118: 515–22.
2. Tuttle T, Jarosek S, Habermann E, et al. Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ. J Clin Oncol. 2009;27:1362–67.
3. Kuerer HM, Albarracin CT, Yang WT, et al. Ductal carcinoma in situ: state of the science and roadmap to advance the field. J Clin Oncol. 2009;27:279–88.
4. Yi M, Hunt K, Arun B, et al. Factors affecting the decision of breast cancer patients to undergo contralateral prophylactic mastectomy. Cancer Prev Res. 2010;3:1026–34.
5. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998;62:676–89.
6. Chen S, Iversen ES, Friebel T, et al. Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol. 2006;24:863–71.
7. Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2004; 22:1055–62.
8. Chung A, Huynh K, Lawrence C, Sim MS, Giuliano A. Comparison of patient characteristics and outcomes of contralateral prophylactic mastectomy and unilateral total mastectomy in breast cancer patients. Ann Surg Oncol. 2012;19:2600–06.
9. Stuckey A, Dizon D, Scalia Wilbur J, et al. Clinical characteristics and choices regarding risk-reducing surgery in BRCA mutation carriers. Gynecol Obstet Invest. 2010;69:270–73.
10. Wainberg S, Husted J. Utilization of screening and preventive surgery among unaffected carriers of a BRCA1 or BRCA2 gene mutation. Cancer Epidemiol Biomark Prev. 2004;13:1989–95.
11. Skytte AB, Gerdes AM, Andersen MK, et al. Risk-reducing mastectomy and salpingo-oophorectomy in unaffected BRCA mutation carriers: uptake and timing. Clin Genet. 2010;77:342–49.
12. Hwang ES, et al. Ductal carcinoma in situ in BRCA mutation carriers. J Clin Oncol. 2007;25:642–47.
13. Lakhani SR, Jacquemier J, Sloane JP, et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst. 1998;90:1138–45.
14. Frank TS, Deffenbaugh AM, Reid JE, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol. 2002;20: 1480–90.
15. National Comprehensive Cancer Network. Genetic/familial high-risk assessment: breast and ovarian (version 1.2013). http://www. nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf. Accessed 7 Nov 2013.
16. Snedecor GW, Cochran WG. Statistical methods. 7th ed. Ames: The Iowa State University Press; 1980.
17. Hosmer DW, Lemeshow S. Applied logistic regression. 2nd ed. New York: Wiley; 2000.
18. Heemskerk-Gerritsen BA, Brekelmans CT, Menke-Pluymers MB, et al. Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic. Ann Surg Oncol. 2007;14:3335–44.
19. Litton JK, et al. Perception of screening and risk reduction surgeries in patients tested for a BRCA deleterious mutation. Cancer 2009;115:1598–604.
20. Meijers-Heijbor H, Van Geel B, Van Putten WL, et al. Breast cancer after prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2001;345:159–64.
21. Hartmann LC, Sellers TA, Schaid DJ, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst. 2001;93:1633–37.
22. Howard-McNatt M, Schroll RW, Hurt GJ, Levine EA. Contra-lateral prophylactic mastectomy in breast cancer patients who test negative for BRCA mutations. Am J Surg. 2011;202:298–302.
23. Goldflam K, Hunt KK, Gershenwald JE, et al. Contralateral prophylactic mastectomy: predictors of significant histologic findings. Cancer. 2004;101:1977–86.
24. Alvarado R, et al. Biology, treatment, and outcome in very young and old women with DCIS. Ann Surg Oncol. 2012;19:3777–84.
25. Montgomery LL, Tran KN, Heelan MC, et al. Issues of regret in women with contralateral prophylactic mastectomies. Ann Surg Oncol. 1999;6:546–52.